Individual difference in drug metabolism and disposition:: Toxicological significance of genotypes and phenotypes of S-mephenytoin 4′-hydroxylase (CYP2C19)

被引:1
|
作者
Ikebuchi, J [1 ]
Yamada, M [1 ]
Ogura, Y [1 ]
Yamamoto, Y [1 ]
Nishimura, A [1 ]
Nishi, K [1 ]
Yamada, K [1 ]
Irizawa, Y [1 ]
机构
[1] Tottori Univ, Fac Med, Dept Legal Med, Yonago, Tottori 6830826, Japan
来源
PROGRESS IN FORENSIC GENETICS 9 | 2003年 / 1239卷
关键词
CYP2C19; genotyping; phenotyping; polymorphism; toxicogenetics;
D O I
10.1016/S0531-5131(02)00389-8
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We examined the relationship between the genetic polymorphism of CYP2C19 and metabolism of omeprazole in order to assess the severity and to predict the outcome of poisoning for forensic and clinical toxicology. The genotypes observed were CYP2C19*1A (wild type), CYP2C19*2 (ml), and CYP2C19*3 (m2). The omeprazole hydroxylation index of the wild-type was -1.15, whereas for the hetero-type it was -0.78, and homo-mutated type 1.22. The genotype of CYP2C19 correlated with the phenotype. The present results proved that genotyping assays of drug metabolizing enzymes are of great value in toxicological significance. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:589 / 592
页数:4
相关论文
共 50 条
  • [1] THE ROLE OF S-MEPHENYTOIN HYDROXYLASE (CYP2C19) IN THE METABOLISM OF THE ANTIMALARIAL BIGUANIDES
    WRIGHT, JD
    HELSBY, NA
    WARD, SA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (04) : 441 - 444
  • [2] ALTERATIONS IN HUMAN CYP2C19, THE MAJOR S-MEPHENYTOIN 4'-HYDROXYLASE, IN POOR METABOLIZERS OF S-MEPHENYTOIN
    GOLDSTEIN, JA
    GHANAYEM, BI
    FALETTO, M
    LASKER, J
    SULLIVAN, T
    ROMKESSPARKS, M
    RAUCY, J
    WILKINSON, G
    MEYER, U
    DEMORAIS, SMF
    FASEB JOURNAL, 1994, 8 (07): : A1257 - A1257
  • [3] Genetic variations of S-mephenytoin 4′-hydroxylase (CYP2C19) in the Chinese population
    Xie, HG
    LIFE SCIENCES, 2000, 66 (14) : PL175 - PL181
  • [4] CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase
    Zhou, HH
    CLINICA CHIMICA ACTA, 2001, 313 (1-2) : 203 - 208
  • [5] IDENTIFICATION OF STRUCTURAL DETERMINANTS OF S-MEPHENYTOIN 4'-HYDROXYLASE ACTIVITY USING CYP2C9/CYP2C19 CHIMERAS
    IBEANU, GC
    GHANAYEM, BI
    LINKO, P
    GOLDSTEIN, JA
    FASEB JOURNAL, 1995, 9 (06): : A1489 - A1489
  • [6] Identification of critical residues of human CYP2C19 as key determinants of S-mephenytoin hydroxylase activity
    Tsao, CC
    Coulter, SJ
    Chanas, B
    Goldstein, JA
    FASEB JOURNAL, 2000, 14 (08): : A1436 - A1436
  • [7] EVIDENCE THAT CYP2C19 IS THE MAJOR (S)-MEPHENYTOIN 4'-HYDROXYLASE IN HUMANS
    GOLDSTEIN, JA
    FALETTO, MB
    ROMKESSPARKS, M
    SULLIVAN, T
    KITAREEWAN, S
    RAUCY, JL
    LASKER, JM
    GHANAYEM, BI
    BIOCHEMISTRY, 1994, 33 (07) : 1743 - 1752
  • [8] S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among ethiopians
    Persson, I
    Aklillu, E
    Rodrigues, F
    Bertilsson, L
    IngelmanSundberg, M
    PHARMACOGENETICS, 1996, 6 (06): : 521 - 526
  • [9] Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes
    Masimirembwa, CM
    Gustafsson, LL
    Dahl, ML
    Abdi, YA
    Hasler, JA
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (04) : 344 - 346
  • [10] CYP2C19 genotype and S-mephenytoin 4′-hydroxylation phenotype in a Chinese Dai population
    Nan He
    Feng-Xiang Yan
    Song-Lin Huang
    Wei Wang
    Zhou-Sheng Xiao
    Zhao-Qian Liu
    Hong-Hao Zhou
    European Journal of Clinical Pharmacology, 2002, 58 : 15 - 18